Hypothalamic Neoplasms: Clinical Trials

4 trials for Hypothalamic Neoplasms, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

4 completed. 4 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 34Completed 4

Follow Hypothalamic Neoplasms: new trials by email Literature Review of Hypothalamic Neoplasms trials Research Report on Hypothalamic Neoplasms

Trials (filtered) newest first · largest first

All 4 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Pasireotide in Patients With Acromegaly Inadequately Controlled With First Generation Somatostatin Analogues
Pasireotide LAR - Acromegaly
Phase 3CompletedNovartis Pharmaceuticals1232015-03-312019-12-10
Cabergoline in Nonfunctioning Pituitary Adenomas
Cabergoline - Pituitary Adenoma, Nonfunctioning Pituitary Adenoma
Phase 3CompletedUniversity of Sao Paulo General Hospital1402015-02-012017-09-07
An Open-label, Multi-center, Expanded Access Study of Pasireotide s.c. in Patients With Cushing's Disease.
Pasireotide sub-cutaneous - Cushing's Disease
Phase 3CompletedNovartis Pharmaceuticals1042011-08-162018-06-19
Efficacy and Safety of Pasireotide Long Acting Release (LAR) Versus Octreotide LAR or Lanreotide Autogel (ATG) in Patients With Inadequately Controlled Acromegaly
Pasireotide, octreotide LAR 30mg, lanreotide ATG 120mg - Acromegaly
Phase 3CompletedNovartis Pharmaceuticals1982010-07-192018-04-05

Narrower conditions

Pituitary Neoplasms (4)  ·  Acromegaly (2)  ·  Gigantism (1)  ·  Growth Disorders (1)  ·  Pituitary ACTH Hypersecretion (1)

Broader conditions

Brain Diseases (4)  ·  Brain Neoplasms (4)  ·  Central Nervous System Diseases (4)  ·  Central Nervous System Neoplasms (4)  ·  Endocrine Gland Neoplasms (4)  ·  Endocrine System Diseases (4)  ·  Hypothalamic Diseases (4)  ·  Neoplasms (4)  ·  Neoplasms by Site (4)  ·  Nervous System Diseases (4)  ·  Nervous System Neoplasms (4)  ·  Pituitary Diseases (4)  ·  Supratentorial Neoplasms (4)  ·  Hyperpituitarism (3)

Interventions

pasireotide (2)  ·  Cabergoline (1)

Sponsors

Novartis Pharmaceuticals (3)  ·  University of Sao Paulo General Hospital (1)

Countries

Brazil (4)  ·  Romania (3)  ·  Argentina (2)  ·  Belgium (2)  ·  Colombia (2)  ·  France (2)  ·  Germany (2)  ·  Italy (2)  ·  Russia (2)  ·  Spain (2)  ·  Turkey (Türkiye) (2)  ·  United Kingdom (2)  ·  United States (2)  ·  Bulgaria (1)  ·  Canada (1)

Top investigators

Rafael L Batista, MD (1)

Results publications

PMID 25260838, PMID 25418156, PMID 27150495, PMID 30540568, PMID 31379734, PMID 32117045, PMID 32217809, PMID 35954244

NIH funding

2014 (1)